Vascular endothelial growth factor is of high prognostic value in node- negative breast carcinoma

Journal of Clinical Oncology

Volumn 16, Issue 9, 1998, Pages 3121-3128

  Linderholm, Barbro ^a   Tavelin, Björn ^a   Grankvist, Kjell ^a   Henriksson, Roger ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TUMOR VOLUME;

EID: 0031671095     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.9.3121     Document Type: Article

References (42)

1. Dexter DL, Kowalsky HM, Blazer BA, et al: Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res 38:3174-3181, 1978
2. Gasparini G, Pozza F, Harris AL: Evaluating the potentional usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206-1219, 1993
3. Gasparini G, Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a prognostic tool. J Clin Oncol 13:765-782, 1995
4. Marx J: Cellular changes on the route to metastasis. Science 259:626-629, 1993
5. Gasparini G, Weidner N, Bevilaqua P: Tumor microvessel density, p53 expression, tumor size and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12:454-466, 1994
6. Weidner N, Folkman J, Pozza, et al: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast cancer. J Natl Cancer Inst 84:1875-1887, 1992
7. Bosari S, Lee AKC, De Lellis RA, et al: Microvessel quantitation of prognosis in invasive breast carcinoma. Hum Pathol 23:755-761, 1992
8. Horak E, Leek R, Klenk N, et al: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies as indicator of node metastases and survival in breast cancer. Lancet 340:1120-1124, 1992
9. Toi M, Kashitani J, Tominaga T, et al: Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55:341-374, 1993
10. Fox SB, Leek RD, Smith K, et al: Tumor angiogenesis in node-negative breast carcinomas - Relationship with epidermal growth factor receptor, estrogen receptor and survival. Breast Cancer Res Treat 29:109-116, 1994
11. Weidner N, Semple SP, Welch WR, et al: Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
12. Ogawa Y, Chung Y-S, Nakata B, et al: Microvessel quantification in invasive breast cancer by staining for factor VIII-related antigen. Br J Cancer 71:1297-1301, 1995
13. Bevilacqua P, Barbareschi M, Verderio P, et al: Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma. Breast Cancer Res Treat 36:205-217, 1995
14. Obermair A, Kurz C, Czerwenka K, et al: Microvessel density and vessel invasion in lymph node-negative breast cancer: Effect on recurrence-free survival. Int J Cancer 62:126-131, 1995
15. Teicher BA, Holden SA, Ara G, et al: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenetic agents. Int J Cancer 57:920-925, 1994
16. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1:27-31, 1995
17. Gasparini G, Toi M, Gion M, et al: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89:139-147, 1997
18. Volpert OV, Stellmach V, Bouck N: The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res Treat 36:119-126, 1995
19. Senger DR, Van De Walter L, Brown LF, et al: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12:303-324, 1993
20. Neufeld G, Tessler S, Weindel K, et al: Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 5:89-97, 1994
21. Vincenti V, Cassano C, Rocchi M, et al: Assignment of the vascular endothelial growth factor gene to the human chromosome 6p21.3. Circulation 93:1493-1495, 1996
22. Tisher E, Mitchell R, Hartman T, et al: The human gene for vascular endothelial growth factor. J Biol Chem 266:11947-11954, 1991
23. Houck KA, Ferrara N, Winer J, et al: The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806-1814, 1991
24. Ferrara N, Houck K, Jakeman L, et al: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrinol Rev 13:18-32, 1992
25. Houck KA, Leung DW, Rowland AM, et al: Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267:26031-26037, 1992
26. Park JE, Keller G-A, Ferrara N: The vascular endothelial growth factor (VEGF) isoforms. Differential deposition into the subepithelial extracellular matrix and bioactivity of ECM-bound VEGF. Mol Biol Cell 4:1317-1326, 1993
27. Consensus Development Panel: Consensus statement: Treatment of early-stage breast cancer. J Natl Cancer Inst Monogr 11:1-5, 1992
28. Osborn CK: Prognostic factors for breast cancer: Have they met their promise? J Clin Oncol 10:679-682, 1992
29. Henderson IC: Breast cancer therapy - The price of success. N Engl J Med 326:1774-1775, 1992
30. Norgren A, Fernö M, Borg Å: Observations on wet weight, protein and DNA as reference for steroid receptors in malignant mammary tumours. Anticancer Res 6:59-64, 1986
31. Sigurdsson H, Baldetorp B, Borg Å, et al: Indicators of prognosis in node-negative breast cancer. N Engl J Med 332:1045-1053, 1990
32. Toi M, Hoshima S, Takayanagi T, et al: Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 85:1045-1049, 1994
33. Toi M, Kondo S, Suzuki H, et al: Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 77:1101-1106, 1996
34. Obermair A, Kucera E, Mayerhofer K, et al: Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease-free survival. Int J Cancer 74:455-458, 1997
35. Schnaper HW, McGowan KA, Kim-Schulze S, et al: Oestrogen and endothelial cell angiogenic activity. Clin Exp Pharmacol Physiol 23:247-250, 1996
36. Banerjee SK, Sarkar DK, Weston AP, et al: Overexpression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis. Carcinogenesis 18:1155-1161, 1997
37. Teicher BA, Holden SA, Ara G, et al: Response of the FSaII fibrosarcoma to antiangiogenetic modulations plus cytotoxic agents. Anticancer Res 13:2101-2106, 1993
38. Macaulay VM, Fox SB, Zhang H, et al: Breast cancer angiogenesis and tamoxifen resistance. Endocr Rel Cancer 2:97-103, 1995
39. Gasparini G, Fox SB, Verderio P, et al: Angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin Cancer Res 2:1191-1198, 1996
40. Gasparini G, Barbareschi M, Boracchi P, et al: Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated either with adjuvant hormone therapy or chemotherapy. Cancer J Sci Am 1:131-141, 1995
41. Teicher BA, Sotomayor EA, Huang ZD, et al: Antiangiogenetic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52:6702-6704, 1992
42. Schlaeppi JM, Eppenberger U, Martiny-Baron G, et al: Chemiluminescence immunoassay for vascular endothelial growth factor (vascular permeability factor) in tumor tissue homogenates. Clin Chem 42:1777-1784, 1996